Ameritas Investment Partners’s CytomX Therapeutics CTMX Stock Holding History

Ameritas Investment Partners’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,010	Closed	-$13K	–	3100
2022 Q1	$13K	Hold	5,010	–	–	﹤0.01%	2707
2021 Q4	$22K	Hold	5,010	–	–	﹤0.01%	2596
2021 Q3	$26K	Hold	5,010	–	–	﹤0.01%	2555
2021 Q2	$32K	Hold	5,010	–	–	﹤0.01%	2464
2021 Q1	$39K	Buy	5,010 +1,321	+36%	+$10.5K	﹤0.01%	2229
2020 Q4	$24K	Hold	3,689	–	–	﹤0.01%	2377
2020 Q3	$25K	Hold	3,689	–	–	﹤0.01%	2257
2020 Q2	$31K	Hold	3,689	–	–	﹤0.01%	2106
2020 Q1	$28K	Hold	3,689	–	–	﹤0.01%	1982
2019 Q4	$31K	Hold	3,689	–	–	﹤0.01%	2175
2019 Q3	$27K	Hold	3,689	–	–	﹤0.01%	2224
2019 Q2	$41K	Hold	3,689	–	–	﹤0.01%	2018
2019 Q1	$40K	Buy	3,689 +450	+14%	+$6.65K	﹤0.01%	2011
2018 Q4	$49K	Hold	3,239	–	–	﹤0.01%	1818
2018 Q3	$60K	Hold	3,239	–	–	﹤0.01%	1883
2018 Q2	$74K	Buy	3,239 +689	+27%	+$17.6K	﹤0.01%	1742
2018 Q1	$73K	Hold	2,550	–	–	﹤0.01%	1691
2017 Q4	$54K	Hold	2,550	–	–	﹤0.01%	1884
2017 Q3	$44K	Hold	2,550	–	–	﹤0.01%	1968
2017 Q2	$40K	Buy	2,550 +959	+60%	+$14.5K	﹤0.01%	2049
2017 Q1	$27K	Buy	+1,591	New	+$20.9K	﹤0.01%	2226

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameritas Investment Partners's CTMX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 5,010 shares — an estimated $13K sold.

Ameritas Investment Partners first reported a position in CTMX in Q1 2017 and held it in 21 quarters. The position peaked at $74K in Q2 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

Ameritas Investment Partners reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 5,010 CytomX Therapeutics shares in Q2 2022, an estimated $13K.
Ameritas Investment Partners first reported a position in CytomX Therapeutics in Q1 2017 and held it in 21 quarters.
Ameritas Investment Partners's CytomX Therapeutics position peaked at $74K in Q2 2018.
98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.